BACKGROUND AND AIM: Sarcoidosis (SA) is a chronic systemic disorder characterized by infiltration of inflammatory cells in affected organs, resulting in the formation of granulomas. Granulomas are observed in numerous infectious diseases and hypersensitivity reactions (e.g., beryllium). Chronic beryllium disease (CBD) is a multisystem entity caused by dust, fumes or mists of beryllium metal or its salts. Although beryllium has been used for years by several industries in Israel, no case of CBD had ever been reported until recently when we described a 21-year-old female dental technician with CBD who was originally diagnosed as having SA. We launched the current investigation to test the hypothesis that other cases of CBD in Israel were not previously reported because these patients were misdiagnosed as having SA. METHODS: Forty-seven patients with confirmed-SA from our outpatient clinic were recalled in order to reevaluate their occupational exposure history. We performed the beryllium lymphocyte transformation test (BeLTT) on each patient with a potentially positive environmental exposure anamnesis to beryllium (14/47). RESULTS: Two of the 14 patients with evidence of granulomas in lung tissue (pulmonary involvement) and 1/14 with extrapulmonary involvement who all had a positive occupational exposure to beryllium and a positive BeLTT test had been erroneously diagnosed as having SA instead of CBD. CONCLUSION: Our findings emphasize the vital importance of taking a comprehensive occupational history in the clinical evaluation of patients suspected of having SA.
BACKGROUND AND AIM: Sarcoidosis (SA) is a chronic systemic disorder characterized by infiltration of inflammatory cells in affected organs, resulting in the formation of granulomas. Granulomas are observed in numerous infectious diseases and hypersensitivity reactions (e.g., beryllium). Chronic beryllium disease (CBD) is a multisystem entity caused by dust, fumes or mists of beryllium metal or its salts. Although beryllium has been used for years by several industries in Israel, no case of CBD had ever been reported until recently when we described a 21-year-old female dental technician with CBD who was originally diagnosed as having SA. We launched the current investigation to test the hypothesis that other cases of CBD in Israel were not previously reported because these patients were misdiagnosed as having SA. METHODS: Forty-seven patients with confirmed-SA from our outpatient clinic were recalled in order to reevaluate their occupational exposure history. We performed the beryllium lymphocyte transformation test (BeLTT) on each patient with a potentially positive environmental exposure anamnesis to beryllium (14/47). RESULTS: Two of the 14 patients with evidence of granulomas in lung tissue (pulmonary involvement) and 1/14 with extrapulmonary involvement who all had a positive occupational exposure to beryllium and a positive BeLTT test had been erroneously diagnosed as having SA instead of CBD. CONCLUSION: Our findings emphasize the vital importance of taking a comprehensive occupational history in the clinical evaluation of patients suspected of having SA.
Authors: Marcos Ribeiro; Leandro G Fritscher; Ahmed M Al-Musaed; Meyer S Balter; Victor Hoffstein; Bruce D Mazer; Lisa A Maier; Gary M Liss; Susan M Tarlo Journal: Lung Date: 2011-03-13 Impact factor: 2.584
Authors: Nancy W Lin; Lisa A Maier; Margaret M Mroz; Sean Jacobson; Kristyn MacPhail; Sucai Liu; Zhe Lei; Briana Q Barkes; Tasha E Fingerlin; Nabeel Hamzeh; Annyce S Mayer; Clara I Restrepo; Divya Chhabra; Ivana V Yang; Li Li Journal: Respir Med Date: 2021-04-05 Impact factor: 4.582
Authors: James A Snyder; Eugene Demchuk; Erin C McCanlies; Christine R Schuler; Kathleen Kreiss; Michael E Andrew; Bonnie L Frye; James S Ensey; Marcia L Stanton; Ainsley Weston Journal: J R Soc Interface Date: 2008-07-06 Impact factor: 4.118
Authors: E Fireman; A Bar Shai; Y Lerman; M Topilsky; P D Blanc; L Maier; L Li; S Chandra; J M Abraham; I Fomin; G Aviram; J L Abraham Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2012-10 Impact factor: 0.670
Authors: Paul D Blanc; Isabella Annesi-Maesano; John R Balmes; Kristin J Cummings; David Fishwick; David Miedinger; Nicola Murgia; Rajen N Naidoo; Carl J Reynolds; Torben Sigsgaard; Kjell Torén; Denis Vinnikov; Carrie A Redlich Journal: Am J Respir Crit Care Med Date: 2019-06-01 Impact factor: 21.405
Authors: Elizabeth Fireman; Amir Bar Shai; Yifat Alcalay; Noa Ophir; Shmuel Kivity; Vera Stejskal Journal: J Occup Med Toxicol Date: 2016-04-12 Impact factor: 2.646